Home

FOLLISTATIN BIOTHERAPEUTICS FOR INFLAMMATION & FIBROSIS

Paranta Biosciences is an early stage drug development company committed to developing and commercializing novel biotherapeutics based on recombinant human follistatin to treat conditions involving inflammation and fibrosis.

A key therapeutic focus for the company is the treatment of respiratory diseases. However we are keen to explore partnering opportunities to assist with development of follistatin to treat other inflammatory and fibrotic conditions.

Leave a Reply